Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 4
2009 2
2010 2
2011 3
2012 9
2013 6
2014 17
2015 16
2016 11
2017 8
2018 9
2019 15
2020 18
2021 14
2022 16
2023 16
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Results by year

Filters applied: . Clear all
Page 1
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Immunotherapy advances in uro-genital malignancies.
Ratta R, Zappasodi R, Raggi D, Grassi P, Verzoni E, Necchi A, Di Nicola M, Salvioni R, de Braud F, Procopio G. Ratta R, et al. Among authors: verzoni e. Crit Rev Oncol Hematol. 2016 Sep;105:52-64. doi: 10.1016/j.critrevonc.2016.06.012. Epub 2016 Jun 17. Crit Rev Oncol Hematol. 2016. PMID: 27372200 Review.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free article. Clinical Trial.
Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma.
Fotia G, Stellato M, Guadalupi V, Sepe P, Claps M, Giannatempo P, Bottiglieri A, Rametta A, Taglialatela I, Vela C, Procopio G, Verzoni E. Fotia G, et al. Among authors: verzoni e. Curr Oncol Rep. 2023 Jun;25(6):671-677. doi: 10.1007/s11912-023-01395-4. Epub 2023 Mar 31. Curr Oncol Rep. 2023. PMID: 37000341 Review.
Biomarker-driven immunotherapy for precision medicine in prostate cancer.
Ottini A, Sepe P, Beninato T, Claps M, Guadalupi V, Verzoni E, Giannatempo P, Baciarello G, de Braud F, Procopio G. Ottini A, et al. Among authors: verzoni e. Per Med. 2022 Jan;19(1):51-66. doi: 10.2217/pme-2021-0079. Epub 2021 Dec 7. Per Med. 2022. PMID: 34873959 Review.
Castration-naive metastatic prostate cancer: reshaping old paradigms.
Ratta R, Grassi P, Fucà G, Verzoni E, Procopio G. Ratta R, et al. Among authors: verzoni e. Expert Rev Anticancer Ther. 2017 Oct;17(10):879-881. doi: 10.1080/14737140.2017.1374178. Epub 2017 Sep 11. Expert Rev Anticancer Ther. 2017. PMID: 28854837 No abstract available.
Treatment of elderly patients with metastatic renal cell carcinoma.
Zanardi E, Grassi P, Cavo A, Verzoni E, Maggi C, De Braud F, Boccardo F, Procopio G. Zanardi E, et al. Among authors: verzoni e. Expert Rev Anticancer Ther. 2016;16(3):323-34. doi: 10.1586/14737140.2016.1131613. Epub 2016 Jan 20. Expert Rev Anticancer Ther. 2016. PMID: 26654225 Review.
Current Understanding of Urachal Adenocarcinoma and Management Strategy.
Claps M, Stellato M, Zattarin E, Mennitto A, Sepe P, Guadalupi V, Mennitto R, de Braud FGM, Verzoni E, Procopio G. Claps M, et al. Among authors: verzoni e. Curr Oncol Rep. 2020 Jan 27;22(1):9. doi: 10.1007/s11912-020-0878-z. Curr Oncol Rep. 2020. PMID: 31989430 Review.
158 results